Laryngoscope investigative otolaryngology · 2026
Cardio-Protective Effect of GLP-1 Agonists in OSA Patients: A Study of Cardiovascular Risk.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lane Morgan, Jin Alex, Andersen Boston, Kadrie Alec, Hebert Sage, Thomson Evan, Gillespie M Boyd
Аннотация
OBJECTIVE: Obstructive sleep apnea (OSA) is highly associated with obesity and often results in significant cardiovascular complications. This study aimed to assess cardiovascular outcomes in OSA patients treated with GLP-1 agonists (GLP1a) versus CPAP.
METHODS: This retrospective cohort analysis using TriNetX datasets (2014-2024) compared cardiovascular outcomes between four pairs of cohorts, after propensity score matching (PSM): OSA+CPAP +/- GLP1a, OSA+Obesity + CPAP +/- GLP1a, OSA-CPAP +/- GLP1a, and OSA+Obesity-CPAP +/- GLP1a. Outcomes of interest include myocardial infarction, heart failure, stroke, cardiac arrest, ventricular arrhythmias, atrial fibrillation/flutter, pulmonary hypertension, and percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).
RESULTS: In the non-CPAP cohort, GLP-1a therapy showed decreased risks of myocardial infarction (RR 0.650 [0.523-0.808]), heart failure (RR 0.500 [0.357-0.701]), cardiac arrest (RR 0.300 [0.199-0.450]), ventricular arrhythmias (RR 0.385 [0.278-0.532]), atrial fibrillation/flutter (RR 0.833 [0.762-0.912]), and PCI/CABG (RR 0.333 [0.163-0.681]). No significant differences were observed in stroke or pulmonary hypertension between GLP1+ and GLP1- groups in this cohort. Among patients using CPAP, GLP1a use was associated with a decreased risk of atrial fibrillation/flutter (RR 0.700 [0.542-0.905]), with no other differences observed.
CONCLUSION: Our study indicates that GLP-1 agonists may offer cardioprotective benefits not achieved with CPAP therapy in OSA patients. Our study indicates that a GLP-1 agonist prescription may be associated with improved cardiovascular outcomes; these associations were not observed with CPAP therapy prescription in OSA patients. Additional research is required to determine whether obesity status modulates the observed benefits among patients with OSA.
METHODS: This retrospective cohort analysis using TriNetX datasets (2014-2024) compared cardiovascular outcomes between four pairs of cohorts, after propensity score matching (PSM): OSA+CPAP +/- GLP1a, OSA+Obesity + CPAP +/- GLP1a, OSA-CPAP +/- GLP1a, and OSA+Obesity-CPAP +/- GLP1a. Outcomes of interest include myocardial infarction, heart failure, stroke, cardiac arrest, ventricular arrhythmias, atrial fibrillation/flutter, pulmonary hypertension, and percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).
RESULTS: In the non-CPAP cohort, GLP-1a therapy showed decreased risks of myocardial infarction (RR 0.650 [0.523-0.808]), heart failure (RR 0.500 [0.357-0.701]), cardiac arrest (RR 0.300 [0.199-0.450]), ventricular arrhythmias (RR 0.385 [0.278-0.532]), atrial fibrillation/flutter (RR 0.833 [0.762-0.912]), and PCI/CABG (RR 0.333 [0.163-0.681]). No significant differences were observed in stroke or pulmonary hypertension between GLP1+ and GLP1- groups in this cohort. Among patients using CPAP, GLP1a use was associated with a decreased risk of atrial fibrillation/flutter (RR 0.700 [0.542-0.905]), with no other differences observed.
CONCLUSION: Our study indicates that GLP-1 agonists may offer cardioprotective benefits not achieved with CPAP therapy in OSA patients. Our study indicates that a GLP-1 agonist prescription may be associated with improved cardiovascular outcomes; these associations were not observed with CPAP therapy prescription in OSA patients. Additional research is required to determine whether obesity status modulates the observed benefits among patients with OSA.